A Study of LY3016859 in Healthy Volunteers

NCT ID: NCT01545583

Last Updated: 2018-07-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-04-30
• Study Completion Date: 2012-09-30

Brief Summary

The purpose of this study is to investigate the safety and tolerability of LY3016859 administered as single doses, and to determine how long LY3016859 remains in the body

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Placebo intravenous

Placebo administered once intravenously

Group Type: PLACEBO_COMPARATOR

Placebo intravenous

Intervention Type: DRUG

Administered intravenously

0.1 milligram (mg) LY3016859 intravenous

0.1 mg LY3016859 administered once intravenously

Group Type: EXPERIMENTAL

LY3016859 intravenous

Intervention Type: DRUG

Administered intravenously

1 mg LY3016859 intravenous

1 mg LY3016859 administered once intravenously

Group Type: EXPERIMENTAL

LY3016859 intravenous

Intervention Type: DRUG

Administered intravenously

10 mg LY3016859 intravenous

10 mg LY3016859 administered once intravenously

Group Type: EXPERIMENTAL

LY3016859 intravenous

Intervention Type: DRUG

Administered intravenously

50 mg LY3016859 intravenous

50 mg LY3016859 administered once intravenously

Group Type: EXPERIMENTAL

LY3016859 intravenous

Intervention Type: DRUG

Administered intravenously

250 mg LY3016859 intravenous

250 mg LY3016859 administered once intravenously

Group Type: EXPERIMENTAL

LY3016859 intravenous

Intervention Type: DRUG

Administered intravenously

750 mg LY3016859 intravenous

750 mg LY3016859 administered once intravenously

Group Type: EXPERIMENTAL

LY3016859 intravenous

Intervention Type: DRUG

Administered intravenously

Placebo subcutaneous

Placebo administered once subcutaneously

Group Type: PLACEBO_COMPARATOR

Placebo subcutaneous

Intervention Type: DRUG

Administered subcutaneously

50 mg LY3016859 subcutaneous

50 mg LY3016859 administered once subcutaneously

Group Type: EXPERIMENTAL

LY3016859 subcutaneous

Intervention Type: DRUG

Administered subcutaneously

Interventions

LY3016859 intravenous

Administered intravenously

Intervention Type: DRUG

Placebo intravenous

Administered intravenously

Intervention Type: DRUG

LY3016859 subcutaneous

Administered subcutaneously

Intervention Type: DRUG

Placebo subcutaneous

Administered subcutaneously

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy men and women of non-childbearing potential as determined by medical history and physical examination (PE), and:

• Men agree to use 2 medically accepted methods of contraception with all sexual partners during the study and for 90 days after the final dose
• Women are not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks after tubal ligation) confirmed by medical history, or post-menopause. Post-menopausal status will be defined as a woman 45 years of age or older with either 12 months of spontaneous amenorrhea, or 6-12 months of spontaneous amenorrhea combined with follicle stimulating hormone (FSH) greater than (>) 40 international units per liter (IU/L)
• Are reliable and are willing to make themselves available for the duration of the study, and are willing to follow site specific study procedures
• Must weigh greater than or equal to (≥) 50 kilograms (kg) at time of screening and dosing
• Have clinical laboratory test results within normal reference range for the investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
• Have venous access sufficient to allow blood sampling as per the protocol
• Must be a non-smoker

Exclusion Criteria

• Are currently enrolled in, or have discontinued within the last 60 days from a clinical trial involving an investigational drug that has not received regulatory approval for any indication, or have received treatment with biologic agents (such as monoclonal antibodies) within 3 months or 5 half-lives of the administered drug (whichever is longer) prior to dosing
• Have previously completed or withdrawn from this study or any other study investigating LY3016859, and have previously received the investigational product
• Have a history or presence of medical illness including but not limited to any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, or any clinically significant laboratory abnormality, that in the judgment of the investigator indicates a medical problem that would preclude study participation
• Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study or have:

• Confirmed corrected QT interval using Fridericia's formula (QTcF) > 450 milliseconds (msec) for men and > 470 msec for women
• Bundle branch blocks or other conduction abnormalities other than mild first-degree atrio-ventricular block
• Irregular rhythms other than sinus arrhythmia or occasional, rare supraventricular ectopic beats
• History of unexplained syncope
• Family history of unexplained sudden death or sudden death due to long QT syndrome
• T-wave configurations are not of sufficient quality for assessing QT interval, as determined by the investigator
• Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies, hepatitis C and/or positive hepatitis C antibody, or Hepatitis B and/or positive Hepatitis B surface antigen
• Show use of any medication with potential to mask allergic response for example (e.g.) antihistamines, systemic glucocorticoids or antipyretic agents) within 3 days of dosing (Note: Acetaminophen or nonsteroidal analgesics for headache may be allowed as needed in the Investigator's judgment. The following medications are also specifically allowed in this study: vitamins at normal replacement doses, hormone replacement therapies e.g. estrogen, thyroid hormone), topical medications with limited systemic effects (e.g. eye drops, skin creams, vaginal antifungals, hemorrhoid preparations, etcetera (etc.), stable preventive therapies for hyperlipidemia and gastric acidity disorders)
• Have donated blood of more than 500 milliliters (mL) within the last month.
• Have an average weekly alcohol intake that exceeds 21 units per week or are unwilling to stop alcohol within 48 hours of entry into study and for the duration of the study [1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits]
• Have an abnormal blood pressure (sitting) defined as diastolic blood pressure (DBP) > 95 or less than (<) 50 millimeters of mercury (mmHg) and/or systolic blood pressure (SBP) > 150 or < 90 mmHg confirmed by at least 1 repeat measurement
• Have evidence of regular use of known drugs of abuse or show positive findings for such use on urinary drug screening
• Will donate blood or participate in another clinical trial within 3 months or 5 half-lives of study drug (whichever is longer) of receiving the last study drug administration

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Eli Lilly and Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT- 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

London, , United Kingdom

Countries

United Kingdom

Other Identifiers

2011-005596-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

I5V-MC-TGAA

Identifier Type: OTHER

Identifier Source: secondary_id

14352

Identifier Type: -

Identifier Source: org_study_id